Area of Focus: Cell and Gene Therapies

ImmunoKey is a seed-stage UK biotechnology company developing a first-in-class platform technology to unlock the potential of CAR T-cell therapy for solid cancers. Backed by a leadership team with proven success in cell therapy development, exit, and clinical implementation, ImmunoKey is poised to unlock new possibilities in cancer immunotherapy.